ClinicalTrials.gov
public full text
Public Domain
Effectiveness and Safety of Spondylitis Related to Inflammatory Bowel Disease
Adalimumab is an antibody treatment that targets and neutralizes a molecule produced in the body that is associated with inflammation, tumor necrosis factor (TNF). This molecule is an important factor in causing the inflammation seen in people with a form of inflammatory spinal arthritis called spondylitis as well as inflammation in the bowel called Crohn's disease. Spondylitis and Crohn's disease tend to go together and this study will assess to what degree this treatment is effective for those patients that have both disorders at the same time.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Danish Multicenter Study of Adalimumab in Spondyloarthritis#910421
- Evaluation of Low Dose Infliximab in Ankylosing Spondylitis (Study P04352)#1139914
- Long-Term Safety of ARQ-151 Cream in Adult Subjects With Chronic Plaque Psoriasis#810418
- Usability of an AI for M923 in Subjects With Moderate to Severe RA#1073128
- The Role of Microbiome on Biological Therapy Efficacy in axSpA and RA#844667
Record · ID 1408580
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive